TLV evaluates thumb ECG screening

TLV (the Swedish Dental and Pharmaceutical Benefits Agency) is evaluating the thumb ECG device from Zenicor as part of a government assignment to evaluate medtech products from a health economics perspective.

TLV will be evaluating thumb ECGs in primary preventive screening for atrial fibrillation, which means identifying patients with atrial fibrillation and being able to provide preventive treatment with anticoagulants, thus avoiding stroke.

Its report is expected to be published in October 2014.

Information från TLV

Sammanfattning av förstudie tum-EKG – TLV